ERBB3 and non-small cell lung carcinoma: Av-203 (Table 5) is an IgG1k humanized anti-HER3 monoclonal antibody that inhibits tumor growth in human cancer models with the level of NRG1 expression predictive of response.[134] A phase I clinical trial in patients with advanced solid tumors, including CRC, NSCLC, and HNSCC, showed that Av-203 is safe and well tolerated below a maximum dose of 20 mg/kg every 2 weeks.[135] One patient with NSCLC had a partial response.